Losartan ameliorates TGF-β1–induced CFTR dysfunction and improves correction by cystic fibrosis modulator therapies

Highly effective modulator therapies dramatically improve the prognosis for those with cystic fibrosis (CF). The triple combination of elexacaftor, tezacaftor, and ivacaftor (ETI) benefits many, but not all, of those with the most common F508del mutation in the CF transmembrane conductance regulator...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Michael D., Bengtson, Charles D., Yoshida, Makoto, Niloy, Asef J., Dennis, John S., Baumlin, Nathalie, Salathe, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Concise Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9151698/
https://www.ncbi.nlm.nih.gov/pubmed/35446787
http://dx.doi.org/10.1172/JCI155241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9151698/
https://www.ncbi.nlm.nih.gov/pubmed/35446787
http://dx.doi.org/10.1172/JCI155241

Ejemplares similares